Abstract | BACKGROUND: METHODS: CONCLUSION:
sPLA(2) inhibition has the potential to exert a favorable effect on the artery wall. The VISTA-16 study will determine whether varespladib methyl has a beneficial impact on cardiovascular events in patients with an acute coronary syndrome.
|
Authors | Stephen J Nicholls, Matthew A Cavender, John J P Kastelein, Gregory Schwartz, David D Waters, Robert S Rosenson, Dianna Bash, Colin Hislop |
Journal | Cardiovascular drugs and therapy
(Cardiovasc Drugs Ther)
Vol. 26
Issue 1
Pg. 71-5
(Feb 2012)
ISSN: 1573-7241 [Electronic] United States |
PMID | 22109255
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Acetates
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Indoles
- Keto Acids
- Pyrroles
- varespladib methyl
- Atorvastatin
- Phospholipases A2, Secretory
|
Topics |
- Acetates
(therapeutic use)
- Acute Coronary Syndrome
(drug therapy)
- Atorvastatin
- Double-Blind Method
- Heptanoic Acids
(therapeutic use)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Indoles
(therapeutic use)
- Inflammation
(drug therapy)
- Keto Acids
- Phospholipases A2, Secretory
(antagonists & inhibitors)
- Pyrroles
(therapeutic use)
|